載入...
Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin
Romidepsin is a histone deacetylase inhibitor approved by the FDA for the treatment of patients with cutaneous or peripheral T-cell lymphoma who have received prior systemic therapy. The objective of this analysis was to evaluate the potential QTc effects of romidepsin. Patients with advanced malign...
Na minha lista:
| 發表在: | Cancer Med |
|---|---|
| Main Authors: | , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
John Wiley & Sons, Ltd
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4559029/ https://ncbi.nlm.nih.gov/pubmed/25914207 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.467 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|